Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -32.43% is 30% below its 2-year average of -25.03%, near the low end of its 2-year range (-33.51%–-18.71%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.98% below its 12-month average of -26.16%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -32.43%.
RETURN ON EQUITY (ROE)
-32.43%
RETURN ON EQUITY (ROE) AVG TTM
-26.16%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.98%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+22.80%
vs the sector median at left
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.49B
Return on Equity (ROE)
-32.43%
TTM Avg
-26.16%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
Return on Equity (ROE)
25.87%
TTM Avg
21.38%
3Y Avg
13.81%
5Y Avg
16.13%
Market Cap
$1.50B
Return on Equity (ROE)
27.24%
TTM Avg
-16.62%
3Y Avg
-27.07%
5Y Avg
-49.65%
Market Cap
$1.50B
Return on Equity (ROE)
45.63%
TTM Avg
28.57%
3Y Avg
-115.12%
5Y Avg
-36.89%
Market Cap
$1.48B
Return on Equity (ROE)
-17.32%
TTM Avg
-19.51%
3Y Avg
-16.07%
5Y Avg
-12.58%
Market Cap
$1.46B
Return on Equity (ROE)
-29.48%
TTM Avg
-5.20%
3Y Avg
-280.62%
5Y Avg
-280.62%
Market Cap
$1.45B
Return on Equity (ROE)
23.70%
TTM Avg
9.74%
3Y Avg
8.98%
5Y Avg
11.20%
Market Cap
$1.54B
Return on Equity (ROE)
28.97%
TTM Avg
13.25%
3Y Avg
22.73%
5Y Avg
32.77%
Market Cap
$1.44B
Return on Equity (ROE)
-7.08%
TTM Avg
-0.64%
3Y Avg
-1.30%
5Y Avg
-2.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.49B | -32.43% | -26.16% | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 25.87% | 21.38% | 13.81% | 16.13% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 27.24% | -16.62% | -27.07% | -49.65% |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 45.63% | 28.57% | -115.12% | -36.89% |
| GH Research PLC (GHRS)vs › | $1.48B | -17.32% | -19.51% | -16.07% | -12.58% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | -29.48% | -5.20% | -280.62% | -280.62% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 23.70% | 9.74% | 8.98% | 11.20% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 28.97% | 13.25% | 22.73% | 32.77% |
| Certara, Inc. (CERT)vs › | $1.44B | -7.08% | -0.64% | -1.30% | -2.08% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -1462.12% | -276.13% | -155.50% | -107.48% |
ROE
-32.4%
ROA
-29.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -32.43% |
| 2026-03-31 | -22.75% |
| 2025-12-31 | -23.00% |
| 2025-09-30 | -19.10% |
| 2025-06-30 | -33.51% |
| 2025-03-31 | -27.88% |
| 2024-12-31 | -25.64% |
| 2024-09-30 | -22.24% |
| 2024-06-30 | -18.71% |
